Vertex Gains EU Approval for ALYFTREK®, a New Daily Cystic Fibrosis Treatment

Vertex Gains EU Approval for ALYFTREK®, a New Daily Cystic Fibrosis Treatment

Vertex Secures EU Approval for ALYFTREK®, a New Once-Daily Treatment for Cystic Fibrosis Vertex Pharmaceuticals announced that the European Commission (EC) has approved ALYFTREK® (deutivacaftor/tezacaftor/vanzacaftor) for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who…

Read MoreVertex Gains EU Approval for ALYFTREK®, a New Daily Cystic Fibrosis Treatment
OS Therapies Reports Positive OST-HER2 Survival Data at Osteosarcoma Conference

OS Therapies Reports Positive OST-HER2 Survival Data at Osteosarcoma Conference

OS Therapies Reports Positive OST-HER2 Survival Data at Osteosarcoma Conference OS Therapies a clinical-stage biopharmaceutical company specializing in immunotherapy and Antibody Drug Conjugates (ADCs), has announced encouraging clinical data from its ongoing Phase 2b clinical trial of OST-HER2, a promising…

Read MoreOS Therapies Reports Positive OST-HER2 Survival Data at Osteosarcoma Conference
DuPont Launches FilmTec™ Hypershell™ for Energy-Efficient Dairy Processing

DuPont Launches FilmTec™ Hypershell™ for Energy-Efficient Dairy Processing

DuPont Unveils FilmTec™ Hypershell™ XP RO Element for Smarter, Greener Dairy Processing DuPont has announced the launch of its latest innovation for the dairy industry—the FilmTec™ Hypershell™ XP RO-8038 element, an advanced reverse osmosis (RO) solution tailored to increase productivity,…

Read MoreDuPont Launches FilmTec™ Hypershell™ for Energy-Efficient Dairy Processing